Sodium-Glucose Co-Transporter 2 Inhibition With Empagliflozin Improves Cardiac Function After Cardiac Arrest in Rats by Enhancing Mitochondrial Energy Metabolism

• Main Authors: Yunke Tan (Author), Kai Yu (Author), Lian Liang (Author), Yuanshan Liu (Author), Fengqing Song (Author), Qiulin Ge (Author), Xiangshao Fang (Author), Tao Yu (Author), Zitong Huang (Author), Longyuan Jiang (Author), Peng Wang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Empagliflozin is a newly developed antidiabetic drug to reduce hyperglycaemia by highly selective inhibition of sodium-glucose co-transporter 2. Hyperglycaemia is commonly seen in patients after cardiac arrest (CA) and is associated with worse outcomes. In this study, we examined the effects of empa...